Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. XRAY
stocks logo

XRAY

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Intellectia AI SwingMax
Intellectia AI SwingMax

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
924.64M
+2.17%
0.290
+11.7%
898.84M
+2.26%
0.395
-8.25%
938.32M
+0.25%
0.470
-9.6%
Estimates Revision
The market is revising Downward the revenue expectations for DENTSPLY SIRONA Inc. (XRAY) for FY2025, with the revenue forecasts being adjusted by -0.27% over the past three months. During the same period, the stock price has changed by -22.91%.
Revenue Estimates for FY2025
Revise Downward
down Image
-0.27%
In Past 3 Month
EPS Estimates for FY2025
Revise Downward
down Image
-13.5%
In Past 3 Month
Stock Price
Go Down
down Image
-22.91%
In Past 3 Month
Wall Street analysts forecast XRAY stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for XRAY is 13.42 USD with a low forecast of 12.00 USD and a high forecast of 17.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
15 Analyst Rating
Wall Street analysts forecast XRAY stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for XRAY is 13.42 USD with a low forecast of 12.00 USD and a high forecast of 17.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Buy
13 Hold
0 Sell
Hold
Current: 11.270
sliders
Low
12.00
Averages
13.42
High
17.00
Current: 11.270
sliders
Low
12.00
Averages
13.42
High
17.00
Barrington
Michael Petusky
Outperform
downgrade
$18 -> $14
2025-11-10
Reason
Barrington
Michael Petusky
Price Target
$18 -> $14
2025-11-10
downgrade
Outperform
Reason
Barrington analyst Michael Petusky lowered the firm's price target on Dentsply Sirona to $14 from $18 and keeps an Outperform rating on the shares. While stating that Dentsply Sirona has "turned into the ultimate 'prove it" story," the firm believes the current valuation reflects "maximum skepticism" and argues that the risk/reward continues to favor investors with patience.
Piper Sandler
Neutral
downgrade
$16 -> $13
2025-11-07
Reason
Piper Sandler
Price Target
$16 -> $13
2025-11-07
downgrade
Neutral
Reason
Piper Sandler lowered the firm's price target on Dentsply Sirona to $13 from $16 and keeps a Neutral rating on the shares. The firm notes the company reported Q3 results, with revenue finishing just ahead of Street but EBITDA and EPS missed. Guidance was cut across the board, and while in part a formality with investors already anticipating such a move, challenges in the U.S. are larger than originally thought, Piper adds.
Baird
Neutral
downgrade
$18 -> $14
2025-11-07
Reason
Baird
Price Target
$18 -> $14
2025-11-07
downgrade
Neutral
Reason
Baird lowered the firm's price target on Dentsply Sirona to $14 from $18 and keeps a Neutral rating on the shares. The firm updated its model following Q3 results which provided many updates by low visibility remains.
JPMorgan
Neutral
downgrade
$14 -> $12
2025-11-07
Reason
JPMorgan
Price Target
$14 -> $12
2025-11-07
downgrade
Neutral
Reason
JPMorgan lowered the firm's price target on Dentsply Sirona to $12 from $14 and keeps a Neutral rating on the shares.
Mizuho
Neutral
downgrade
$16 -> $13
2025-11-07
Reason
Mizuho
Price Target
$16 -> $13
2025-11-07
downgrade
Neutral
Reason
Mizuho lowered the firm's price target on Dentsply Sirona to $13 from $16 and keeps a Neutral rating on the shares.
Morgan Stanley
Erin Wright
Equal Weight
downgrade
$14 -> $12
2025-11-07
Reason
Morgan Stanley
Erin Wright
Price Target
$14 -> $12
2025-11-07
downgrade
Equal Weight
Reason
Morgan Stanley analyst Erin Wright lowered the firm's price target on Dentsply Sirona to $12 from $14 and keeps an Equal Weight rating on the shares.
See All Ratings

Valuation Metrics

The current forward P/E ratio for DENTSPLY SIRONA Inc (XRAY.O) is 7.26, compared to its 5-year average forward P/E of 16.11. For a more detailed relative valuation and DCF analysis to assess DENTSPLY SIRONA Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
Undervalued
5Y Average PE
16.11
Current PE
7.26
Overvalued PE
21.33
Undervalued PE
10.90

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
11.97
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
14.95
Undervalued EV/EBITDA
8.99

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
1.92
Current PS
0.00
Overvalued PS
2.72
Undervalued PS
1.12
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %
N/A
ROIC

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
AI Stock Picker
AI Stock Picker

XRAY News & Events

Events Timeline

(ET)
2025-11-06
08:09:51
Dentsply Sirona announces Q3 adjusted EPS of 37 cents, falling short of consensus estimate of 45 cents.
select
2025-10-14 (ET)
2025-10-14
18:46:30
Dentsply Sirona announces that the SEC will not pursue any actions against the company.
select
2025-10-02 (ET)
2025-10-02
08:34:43
Dentsply Sirona Names Denti as Chief Commercial Officer
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
8.0
12-02NASDAQ.COM
DENTSPLY SIRONA Recognized as Leading Dividend Stock with Insider Purchases and 5.64% Yield (XRAY)

  • Insider Buying Insight: The article highlights the significance of insider buying, noting that company officers and directors often invest in their own stocks when they believe the shares are undervalued or the company is progressing well. DENTSPLY SIRONA Inc (XRAY) is mentioned as a company with recent insider buying by Director Leslie F. Varon.

  • Stock Performance: Varon purchased 9,337 shares of XRAY at $10.71 each, and the stock is currently trading at $11.29, reflecting a slight increase. The report also provides a comparison of XRAY's 52-week price range and its performance against the 200-day moving average.

  • Valuation Metrics: DENTSPLY SIRONA Inc is noted for its attractive valuation metrics, including a price-to-book ratio of 1.5 and an annual dividend yield of 5.64%, which is higher than the average in the coverage universe. The company has a strong quarterly dividend history and favorable long-term growth rates.

  • Investment Strategy: The report emphasizes the importance of researching profitable companies with attractive valuations for dividend investors. It aims to provide a list of top-ranked stocks based on profitability and valuation metrics to assist investors in their research.

[object Object]
Preview
5.0
11-25SeekingAlpha
Dentsply Sirona Rises Following Appointment of Interim CFO

  • Leadership Change: Dentsply Sirona has appointed Michael Pomeroy as interim CFO, who will assist CEO Daniel T. Scavilla until a permanent CFO is found.

  • Stock Performance: Following the announcement, Dentsply Sirona's stock increased by 2.3%.

[object Object]
Preview
6.5
11-23Yahoo Finance
Analysts Predict a Shift in DENTSPLY SIRONA's Narrative Due to Revised Targets and Emerging Risks

  • Fair Value Estimate Decline: DENTSPLY SIRONA's fair value estimate has decreased from $16 to approximately $13, reflecting a higher risk premium due to operational and market challenges.

  • Analyst Perspectives: Analysts express mixed views, with UBS maintaining a Buy rating and a $23 price target, while others like JPMorgan and Piper Sandler have lowered their targets, citing ongoing challenges and a need for improved execution.

  • Leadership Changes and Financial Adjustments: The company announced the departure of CFO Matthew E. Garth and reported significant noncash impairment charges, alongside a revised earnings guidance forecasting a decline in sales.

  • Market Sentiment and Future Outlook: Wall Street analysts are currently cautious about DENTSPLY SIRONA's near-term prospects, emphasizing the importance of management's new strategies and execution for potential long-term recovery.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is DENTSPLY SIRONA Inc (XRAY) stock price today?

The current price of XRAY is 11.27 USD — it has decreased -0.57 % in the last trading day.

arrow icon

What is DENTSPLY SIRONA Inc (XRAY)'s business?

DENTSPLY SIRONA Inc. is a manufacturer of professional dental products and technologies. It develops, manufactures, and markets a comprehensive solutions offering including dental and oral health products as well as other consumable medical devices. Its Connected Technology Solutions segment includes design, manufacture and sales of its dental technology and equipment products. Its Essential Dental Solutions segment includes the development, manufacture and sales of its value-added endodontic, restorative, and preventive consumable products and small equipment used by dental professionals for the treatment of patients. Its Orthodontic and Implant Solutions segment includes the design, manufacture, and sales of its various digital implant systems and dental implant products, digital dentures and dental professional-directed aligner solutions. Its Wellspect Healthcare segment includes the design, manufacture, and sales of its continence care solutions for urinary and bowel management.

arrow icon

What is the price predicton of XRAY Stock?

Wall Street analysts forecast XRAY stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for XRAY is 13.42 USD with a low forecast of 12.00 USD and a high forecast of 17.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is DENTSPLY SIRONA Inc (XRAY)'s revenue for the last quarter?

DENTSPLY SIRONA Inc revenue for the last quarter amounts to 904.00M USD, decreased -4.94 % YoY.

arrow icon

What is DENTSPLY SIRONA Inc (XRAY)'s earnings per share (EPS) for the last quarter?

DENTSPLY SIRONA Inc. EPS for the last quarter amounts to -2.14 USD, decreased -13.01 % YoY.

arrow icon

What changes have occurred in the market's expectations for DENTSPLY SIRONA Inc (XRAY)'s fundamentals?

The market is revising Downward the revenue expectations for DENTSPLY SIRONA Inc. (XRAY) for FY2025, with the revenue forecasts being adjusted by -0.27% over the past three months. During the same period, the stock price has changed by -22.91%.
arrow icon

How many employees does DENTSPLY SIRONA Inc (XRAY). have?

DENTSPLY SIRONA Inc (XRAY) has 14000 emplpoyees as of December 05 2025.

arrow icon

What is DENTSPLY SIRONA Inc (XRAY) market cap?

Today XRAY has the market capitalization of 2.25B USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free